TrialSignal transduction and targeted therapy2024

QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study.

Yan Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.